Inovio Pharmaceuticals, Inc. (INO) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped INO stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Inovio Pharmaceuticals is poised for significant growth due to its strong focus on DNA medicines, partnerships, recent regulatory progress, and its ability to meet earnings expectations. Analyst consensus signals strong confidence in the stock, supported by a robust pipeline targeting high-impact market segments. While there are risks, particularly with regulatory scrutiny and competition, the overall outlook is bullish with promising long-term potential. The saved 1-year distribution is P10 $1.2, P50 $2.4, and P90 $6.5.
Last analyzed · Model: gpt-4o
Inovio Pharmaceuticals, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $1.2 | Pessimistic plausible scenario |
| P50 | $2.4 | Median scenario |
| P90 | $6.5 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Inovio Pharmaceuticals has significant positive catalysts, including recent trial successes and funding, but faces risks such as regulatory delays and competition. Considering the high growth potential of its product pipeline and positive analyst sentiment, the outlook leans bullish.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this INO analysis generated?
May 10, 2026.
Is this a guaranteed INO prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full INO stock analysis · INO sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.